



ASX / MEDIA RELEASE

8th March 2016

SORAMIC Study Completes Patient Recruitment

Sydney, Australia; 8th March 2016 – Sirtex Medical Limited (ASX:SRX) today announced the completion of patient recruitment for the SORAMIC study in patients with inoperable primary liver cancer, also known as hepatocellular carcinoma or HCC.

Professor Jens Rieke, global Co-Principal Investigator of the SORAMIC study and director of the Clinic for Radiology and Nuclear Medicine at the University of Magdeburg, said that “For the past ten years, sorafenib has been the sole standard of care for treating patients with advanced HCC, or any HCC that has spread beyond the liver. We hope that the results of this large RCT will demonstrate that the combination of sorafenib and SIR-Spheres microspheres may provide a new treatment standard for patients with HCC who are not eligible for surgical resection or ablation.”

Mr Gilman Wong, Chief Executive Officer of Sirtex Medical commented “SORAMIC is the fourth clinical study to complete patient recruitment across our five major clinical studies program, and represents the largest SIR-Spheres[®] Y-90 resin microspheres combination study ever undertaken in HCC. We eagerly await the results of the study, which are anticipated to be available in 2018.”

The primary endpoint of the SORAMIC study is Overall Survival (OS) with key secondary endpoints of quality of life and safety. A total of 420 patients were recruited into the palliative arm of the study.

A full copy of the University of Magdeburg press release on the SORAMIC study can be found at the following link: <http://www.prnewswire.co.uk/news-releases/major-liver-cancer-study-completes-palliative-cohort-enrolment-571248261.html>

About SORAMIC

The Sorafenib and Micro-therapy Guided by Primovist[®] Enhanced MRI in Patients with Inoperable Liver Cancer (SORAMIC) study combines the most promising novel diagnostic and therapeutic approaches in HCC treatment available to date: diagnosis with hepatocyte specific contrast agent Primovist[®]; microtherapy with SIRT (Y90 radioembolisation) or radiofrequency ablation; and systemic treatment with tyrosine kinase inhibitor sorafenib. ClinicalTrials.gov Identifier: NCT01126645. www.soramic.de.

About Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) is the most common form of primary liver cancer – cancer that starts in the liver. It is the sixth most common cancer in the world and the second most common cause of cancer-related death¹.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Approximately 61,000 doses have been supplied to treat patients with liver cancer at more than 950 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Mr Gilman Wong
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Media Enquiries:

Tim Allerton or Andrew Geddes
City PR
Phone: +61 (0) 2 9267 4511

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

¹ GLOBOCAN 2012. Estimated cancer mortality, incidence and prevalence worldwide. <http://globocan.iarc.fr/Default.aspx>